Oxcarbazepine (All indications)

Study	Exclusion reasons	Rmk	Reference
Vajda (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2018		Overlapping between Vajda 2024a (1999 - 2023) and Vajda 2018 (1999 - 2016) based on the same register and for the almost same outcome (with or without elective termination) => Use of Vajda 2024a because accounting for more relevant confounders.	Vajda Acta Neurol Scand 2018; 137:20-23 10.1111/ane.12816
Vajda (Oxcarbazepine) (Controls unexposed, sick), 2018		Overlapping between Vajda 2024a (1999 - 2023) and Vajda 2018 (1999 - 2016) based on the same register and for the almost same outcome (with or without elective termination) => Use of Vajda 2024a because accounting for more relevant confounders.	Vajda Acta Neurol Scand 2018; 137:20-23 10.1111/ane.12816
Christensen (Oxcarbazepine) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2019		Indications not specified. Overlapping: For ADHD: Christensen 2019 totally included in a larger study published by Dreier 2023 (longer study period and 5 countries) => use of Dreier 2023 data.	Christensen JAMA Netw Open 2019; 2:e186606 10.1001/jamanetworkopen.2018.6606
Christensen (Oxcarbazepine) (Controls unexposed NOS) (Indications NOS), 2019		Indications not specified. Overlapping: For ADHD: Christensen 2019 totally included in a larger study published by Dreier 2023 (longer study period and 5 countries) => use of Dreier 2023 data.	Christensen JAMA Netw Open 2019; 2:e186606 10.1001/jamanetworkopen.2018.6606
Coste (Oxcarbazepine) (Controls unexposed, sick), 2020		EXCLUDED: this control group doesn't exist in the article (only in the report). Children with a diagnosis of brain malformation (ICD-10 codes Q00 to Q04 and Q05.0 to Q05.4) during their stay in the maternity unit are excluded.	Coste Sci Rep 2020; 10:17362 10.1038/s41598-020-74409-x
Daugaard (Oxcarbazepine) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2020		Indications not specified. Overlapping between Bjork 2022 and Daugaard 2020 for Intellectual disabilities (2 outcomes), with more pregnancies in Bjork 2022 because longer study period and 5 countries => use of Bjork 2022 data.	Daugaard JAMA Netw Open 2020; 3:e2025570 10.1001/jamanetworkopen.2020.25570
Daugaard (Oxcarbazepine) (Controls unexposed NOS) (Indications NOS), 2020		Indications not specified. Overlapping between Bjork 2022 and Daugaard 2020 for Intellectual disabilities (2 outcomes), with more pregnancies in Bjork 2022 because longer study period and 5 countries => use of Bjork 2022 data.	Daugaard JAMA Netw Open 2020; 3:e2025570 10.1001/jamanetworkopen.2020.25570
He (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2017	repeat population groups, duplicate reports (most recent study included)	Patients who developed epilepsy during pregnancy or after delivery were not included. Overlapping: He 2017 totally included in Li 2023, with a longer study period and more pregnancies => Use of Li 2023.	He Epilepsy Behav 2017; 74:10-14 10.1016/j.yebeh.2017.05.034
He (Oxcarbazepine) (Controls unexposed, sick), 2017	repeat population groups, duplicate reports (most recent study included)	Patients who developed epilepsy during pregnancy or after delivery were not included. Overlapping: He 2017 totally included in Li 2023, with a longer study period and more pregnancies => Use of Li 2023.	He Epilepsy Behav 2017; 74:10-14 10.1016/j.yebeh.2017.05.034
Vajda b (Oxcarbazepine) (Epilepsy), 2024	same data already obtained by other studies	EXCLUDED: Partial overlapping with Battino 2024, no details on the period of exposure during pregnancy, and congenital malformations reported in Vajda 2019 (with T1 exposure).